15 Oct 2025

"Kirkland & Ellis Advises Plexus Capital on Successful Fundraising of Over $1.3 Billion"

"Kirkland & Ellis successfully advised Plexus Capital, LLC on the early and above-target closings of Plexus Fund VII and Plexus Equity Fund II, raising over $1.3 billion in total. Fund VII secured $977 million, exceeding its $750 million goal, while Equity Fund II raised $345 million, surpassing its $250 million target. These funds will continue Plexus' strategy of investing in profitable lower middle market businesses in the U.S., with Fund VII focusing on structured capital and Equity Fund II on control buyouts in essential services industries."

Kirkland & Ellis advised Plexus Capital, LLC on the successful final closings of Plexus Fund VII and Plexus Equity Fund II, which were completed ahead of schedule and exceeded initial fundraising targets. The transaction involved the establishment of two new investment funds, collectively raising over $1.3 billion in total capital. Plexus Fund VII raised $977 million, surpassing its target of $750 million, while Plexus Equity Fund II raised $345 million, exceeding its target of $250 million. Fund VII focuses on structured capital investments in profitable lower middle market companies in the U.S., while Equity Fund II is aimed at control buyouts in business and essential services industries. The Kirkland team included investment funds lawyers Adam Parks, Brian Allen, and Gabrielle Kornblau; tax lawyer Brandon Short; and investment funds regulatory lawyers Chris Pristouris and Daniel Kahl.
Read the full story

Register for free to access daily news.

Register Free
We use cookies to improve your experience, analyze traffic, and serve targeted ads. Read our Cookie Policy.

Cookie Preferences

Customize your cookie settings. Necessary cookies are always enabled.

Strictly Necessary

Required for the website to function (e.g. login, security).

Analytics & Statistics

Help us understand how visitors interact with the website.

Marketing & Ads

Used to deliver relevant ads and track effectiveness.